Skip to main content

Table 1 Participant characteristics compared between the ankylosing spondylitis and psoriatic arthritis groups

From: Association between syndesmophyte and metabolic syndrome in patients with psoriatic arthritis or ankylosing spondylitis: a cross-sectional study

Characteristics All
(n = 319)
Ankylosing spondylitis
(n = 153)
Psoriatic arthritis
(n = 166)
p-value†
Age (yrs), mean ± SD 45.5 ± 12.2 41.7 ± 11.2 49.0 ± 12.1 < 0.001
Female gender, n (%) 148 (46.4%) 59 (38.6%) 89 (53.6%) 0.007
Disease duration (yrs), median (IQR) 5.0 (8.0) 10.0 (15.0) 3.0 (5.8) < 0.001
Hypertension, n (%) 71 (22.3%) 25 (16.3%) 46 (27.7%) 0.015
Diabetes, n (%) 34 (10.7%) 6 (3.9%) 28 (16.9%) < 0.001
Dyslipidemia, n (%) 54 (16.9%) 18 (11.8%) 36 (21.7%) 0.018
Current smoker, n (%) 27 (8.5%) 12 (7.8%) 15 (9.0%) 0.702
Ex-smoker, n (%) 28 (8.8%) 10 (6.5%) 18 (10.8%) 0.240
Current exercise, n (%) 134 (42.0%) 70 (45.8%) 64 (38.6%) 0.193
Occupational physical work, n (%) 122 (38.2%) 49 (32.0%) 73 (44.0%) 0.028
BMI (kg/m2), mean ± SD 24.4 ± 4.9 23.4 ± 4.9 25.3 ± 4.7 0.001
ASDAS-CRP, mean ± SD 2.1 ± 1.1 2.1 ± 1.1 1.9 ± 1.1 0.993
No. of SynAnk, median (IQR) 3.0 (8.5) 2.5 (11.0) 4.0 (8.0) 0.755
Current DMARDs, median (IQR) 1.0 (0) 1.0 (1.0) 1.0 (1.0) 0.424
Current NSAIDs, n (%) 115 (36.1%) 34 (33.7%) 81 (37.2%) 0.546
  1. A p-value < 0.05 indicates statistical significance
  2. †Reflects comparison between ankylosing spondylitis and psoriatic arthritis
  3. Abbreviations: SD Standard deviation; IQR Interquartile range; BMI Body mass index; ASDAS-CRP Ankylosing Spondylitis Disease Activity - C-reactive protein; SynAnk Syndesmophyte or ankylosis; DMARDs Disease-modifying antirheumatic drugs; NSAIDs Non-steroidal anti-inflammatory drugs